iRegene Therapeutics announced promising NouvNeu001 Phase I clinical data - Thailand PR News - [Banking](https://thailandbusinessnews.net/category/banking/) - [Companies](https://thailandbusinessnews.net/category/companies/) - [Economy](https://thailandbusinessnews.net/category/economy/) - [Press Releases](https://thailandbusinessnews.net/category/press-release/) - [PR Newswire](https://thailandbusinessnews.net/pr-newswire-updates/) - [Tech](https://thailandbusinessnews.net/category/tech/) - [Tourism](https://thailandbusinessnews.net/category/tourism/) - [Press Release](https://thailandbusinessnews.net/category/press-release/) # iRegene Therapeutics announced promising NouvNeu001 Phase I clinical data ##### Up next ###### [Harvest Capital Invests US$40 Million in CHANDO Group, Marking a New Chapter for the Leading China Beauty Brand](https://thailandbusinessnews.net/press-release/harvest-capital-invests-us40-million-in-chando-group-marking-a-new-chapter-for-the-leading-china-beauty-brand/) Published on 13 October 2025 ##### Author ##### [ CISION PRNewswire ](https://thailandbusinessnews.net/author/cision/) ##### Tags - [PRNewswire](https://thailandbusinessnews.net/tag/prnewswire/) CHENGDU, China, Oct. 13, 2025 /PRNewswire/ — iRegene Therapeutics Co., Ltd. ("iRegene" or the "Company") is recognized as a biotechnology company pioneering chemically induced allogeneic cell therapy. iRegene’s lead product, NouvNeu001, is the 1st iPSC therapy to receive IND approval from both the NMPA and the FDA to treat Parkinson’s disease (PD). Recently, NouvNeu001 Phase I clinical data were presented at the International Congress of Parkinson’s Disease and Movement Disorders (MDS). Excellent safety and tolerability were observed for up to 15 months post-transplantation, notably without the use of immunosuppressants after the sixth month. NouvNeu001 was administered via a stereotactically guided procedure, with bilateral injections into the posterior putamen through a single injection trajectory per hemisphere. PET imaging confirmed the long-term engraftment, survival and maturation of the transplanted cells. Significant clinical efficacy was observed, including marked improvements in MDS-UPDRS Part III motor scores. In the low-dose cohort, UPDRS-III scores improved by an average of 30.6 points in the OFF state (a 52.82% improvement from baseline) and 12.9 points in the ON state (a 54.67% improvement from baseline）at 12 months post-transplantation. Similarly, in the high-dose cohort, scores decreased by an average of 23.3 points (OFF) and 9.67 points (ON) at 9 months post-transplantation. These improvements were statistically significant, with continued improvement observed through 15 months post-treatment. Dr. Meng Cai, Chief Medical Officer of iRegene Therapeutics, explained why the Phase I results of NouvNeu001 are so promising. He stated: "The encouraging outcomes from the Phase I trial of NouvNeu001 can be attributed to iRegene’s unique chemical induction platform and optimized clinical strategies. iRegene uses a proprietary chemical inducer cocktail to generate high-purity A9 dopaminergic progenitor cells with enhanced functionality. In addition, the surgical procedure was specifically designed to utilize a single injection trajectory per hemisphere, significantly reducing potential surgical risks and related adverse events." Dr. Jun Wei, Chief Executive Officer of iRegene Therapeutics, added: "The iRegene team is greatly encouraged by this important milestone. We remain fully committed to advancing the completion of the Phase II clinical trial and the international multi-center Phase I clinical trial，and achieving the next milestones in our mission to bring transformative therapies to patients with Parkinson’s disease." About NouvNeu001 iRegene’s flagship product, NouvNeu001, is the world’s first clinical-stage, iPSC-derived, allogeneic dopaminergic progenitor cell therapy for PD. NouvNeu001 received the China NMPA’s IND clearance to initiate Phase I/II in China on Aug 2023, and received the FDA IND clearance to initiate Phase I in USA on June 2024. In April 2025, iRegene launched a multicenter Phase II clinical trial in China (NCT06167681). On August 15, 2025, NouvNeu001 was granted Fast Track Designation (FTD) from the U.S. FDA, becoming the first allogeneic iPSC-derived PD cell therapy worldwide to earn this recognition. This milestone follows the FDA’s Special Exemption (SE) granted in March 2024, further validating iRegene’s clinical data integrity, product quality system, and innovative therapeutic approach. About iRegene Therapeutics Founded in 2017 by a team of international professionals, iRegene Therapeutics is the earliest biotech in the world to apply " Chemical induction" to precisely reprogram cell fate and optimize cellular functions. Leveraging this breakthrough platform, iRegene Therapeutics has built a robust pipeline targeting currently "incurable" diseases such as Parkinson’s disease and blindness. As a leader in chemical induction, iRegene’s proprietary system enables the efficient easy generation of human specific cell types with high purity, and enhanced cellular functionality, pioneering the next generation of chemically derived cell therapies. [Source link ](https://www.prnasia.com/story/archive/4795945_CN95945_0?rand=89749) ``` This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network ``` ##### You May Also Like [](https://thailandbusinessnews.net/press-release/blockpass-and-rwa-inc-partner-to-effect-verifiable-trust-in-real-world-asset-depin-tokenization/) ![Blockpass and RWA Inc. Partner to Effect Verifiable Trust in Real World Asset & DePIN Tokenization](https://i0.wp.com/thailandbusinessnews.net/wp-content/uploads/2025/10/Blockpass-and-RWA-Inc-Partner-to-Effect-Verifiable-Trust-in.jpg?resize=245%2C74&ssl=1 "Blockpass and RWA Inc. Partner to Effect Verifiable Trust in Real World Asset & DePIN Tokenization") - [Press Release](https://thailandbusinessnews.net/category/press-release/) ## Blockpass and RWA Inc. Partner to Effect Verifiable Trust in Real World Asset & DePIN Tokenization HONG KONG, Oct 17, 2025 – (ACN Newswire) – Web3 regtech Blockpass,… - [ACN Newswire](https://thailandbusinessnews.net/author/acnnewswire/ "View all posts by ACN Newswire") - October 21, 2025 [](https://thailandbusinessnews.net/press-release/kroll-announces-intention-to-acquire-madison-pacific-group/) ## Kroll Announces Intention to Acquire Madison Pacific Group Acquisition Reinforces Kroll’s Commitment to Global Agency and Trustee Services and Asia… - [CISION PRNewswire](https://thailandbusinessnews.net/author/cision/ "View all posts by CISION PRNewswire") - July 3, 2025 [](https://thailandbusinessnews.net/press-release/netease-inc-announces-filing-of-annual-report-on-form-20-f-for-fiscal-year-2023-and-publication-of-2023-environmental-social-and-governance-report/) ![NetEase, Inc. Announces Filing of Annual Report on Form 20-F for Fiscal Year 2023 and Publication of 2023 Environmental, Social and Governance Report](https://i0.wp.com/thailandbusinessnews.net/wp-content/uploads/2023/10/SSampC-Completes-Acquisition-of-Iress039-Managed-Funds-Administration-Business.jpg?resize=260%2C140&ssl=1 "NetEase, Inc. Announces Filing of Annual Report on Form 20-F for Fiscal Year 2023 and Publication of 2023 Environmental, Social and Governance Report") - [Press Release](https://thailandbusinessnews.net/category/press-release/) ## NetEase, Inc. Announces Filing of Annual Report on Form 20-F for Fiscal Year 2023 and Publication of 2023 Environmental, Social and Governance Report HANGZHOU, China, April 25, 2024 /PRNewswire/ — NetEase, Inc. ("NetEase" or "the Company,"… - [CISION PRNewswire](https://thailandbusinessnews.net/author/cision/ "View all posts by CISION PRNewswire") - April 25, 2024 ##### Most Read - [![DBS Hong Kong Partners with Visa, Preface to empower Customers with AI Readiness skills, for the Future of Intelligent Payments](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/dbs-hong-kong-partners-with-visa-preface-to-empower-customers-with-ai-readiness-skills-for-the-future-of-intelligent-payments/ "DBS Hong Kong Partners with Visa, Preface to empower Customers with AI Readiness skills, for the Future of Intelligent Payments") [DBS Hong Kong Partners with Visa, Preface to empower Customers with AI Readiness skills, for the Future of Intelligent Payments](https://thailandbusinessnews.net/press-release/dbs-hong-kong-partners-with-visa-preface-to-empower-customers-with-ai-readiness-skills-for-the-future-of-intelligent-payments/ "DBS Hong Kong Partners with Visa, Preface to empower Customers with AI Readiness skills, for the Future of Intelligent Payments") - [![Piramal Pharma Limited Completes Acquisition of Controlling Stake in Yapan Bio Private Limited](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/piramal-pharma-limited-completes-acquisition-of-controlling-stake-in-yapan-bio-private-limited/ "Piramal Pharma Limited Completes Acquisition of Controlling Stake in Yapan Bio Private Limited") [Piramal Pharma Limited Completes Acquisition of Controlling Stake in Yapan Bio Private Limited](https://thailandbusinessnews.net/press-release/piramal-pharma-limited-completes-acquisition-of-controlling-stake-in-yapan-bio-private-limited/ "Piramal Pharma Limited Completes Acquisition of Controlling Stake in Yapan Bio Private Limited") - [![ZTO Reports Second Quarter 2026 Unaudited Financial Results](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/zto-reports-second-quarter-2026-unaudited-financial-results/ "ZTO Reports Second Quarter 2026 Unaudited Financial Results") [ZTO Reports Second Quarter 2026 Unaudited Financial Results](https://thailandbusinessnews.net/press-release/zto-reports-second-quarter-2026-unaudited-financial-results/ "ZTO Reports Second Quarter 2026 Unaudited Financial Results") - [![GSK's Blenrep (belantamab mafodotin) combinations approved in Singapore for treatment of relapsed/refractory multiple myeloma](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/gsks-blenrep-belantamab-mafodotin-combinations-approved-in-singapore-for-treatment-of-relapsed-refractory-multiple-myeloma/ "GSK's Blenrep (belantamab mafodotin) combinations approved in Singapore for treatment of relapsed/refractory multiple myeloma") [GSK's Blenrep (belantamab mafodotin) combinations approved in Singapore for treatment of relapsed/refractory multiple myeloma](https://thailandbusinessnews.net/press-release/gsks-blenrep-belantamab-mafodotin-combinations-approved-in-singapore-for-treatment-of-relapsed-refractory-multiple-myeloma/ "GSK's Blenrep (belantamab mafodotin) combinations approved in Singapore for treatment of relapsed/refractory multiple myeloma") - [![Everest Medicines Announces Interim Results for First Half of 2026](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/everest-medicines-announces-interim-results-for-first-half-of-2026/ "Everest Medicines Announces Interim Results for First Half of 2026") [Everest Medicines Announces Interim Results for First Half of 2026](https://thailandbusinessnews.net/press-release/everest-medicines-announces-interim-results-for-first-half-of-2026/ "Everest Medicines Announces Interim Results for First Half of 2026") - [![Taiwantrade.com Brings Taiwan's ICT Excellence to COMPUTEX 2025](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/taiwantrade-com-brings-taiwans-ict-excellence-to-computex-2025/ "Taiwantrade.com Brings Taiwan's ICT Excellence to COMPUTEX 2025") [Taiwantrade.com Brings Taiwan's ICT Excellence to COMPUTEX 2025](https://thailandbusinessnews.net/press-release/taiwantrade-com-brings-taiwans-ict-excellence-to-computex-2025/ "Taiwantrade.com Brings Taiwan's ICT Excellence to COMPUTEX 2025") ##### Subscribe via Email Enter your email address to subscribe and receive notifications of new posts by email. Email Address Subscribe [](https://thailandbusinessnews.net/press-release/robo-ai-inc-provides-business-update-and-announces-interim-report-release-schedule/) ## Robo.ai Inc. Provides Business Update and Announces Interim Report Release Schedule Company Continues Structural Repositioning, with Shareholders’ Equity Expected to… [](https://thailandbusinessnews.net/press-release/daqo-new-energy-announces-unaudited-second-quarter-2026-financial-results/) ## Daqo New Energy Announces Unaudited Second Quarter 2026 Financial Results SHANGHAI, Aug. 20, 2026 /PRNewswire/ — Daqo New Energy Corp. (NYSE: DQ)… [](https://thailandbusinessnews.net/press-release/yomo-secures-initial-banking-licence-ready-to-lead-egypts-digital-banking-evolution/) ![yomo Secures Initial Banking Licence, Ready to Lead Egypt's Digital Banking Evolution](https://i0.wp.com/mmx.prnasia.com/media/MS1972952/Rashwan-Launch-v-Final.jpg?resize=260%2C140&ssl=1 "yomo Secures Initial Banking Licence, Ready to Lead Egypt's Digital Banking Evolution") ## yomo Secures Initial Banking Licence, Ready to Lead Egypt's Digital Banking Evolution CIB-backed digital banking platform, yomo, set to make managing money simpler, more… [](https://thailandbusinessnews.net/press-release/binance-introduces-agent-os-to-connect-ai-applications-to-financial-infrastructure/) ![Binance Introduces Agent OS to Connect AI Applications to Financial Infrastructure](https://i0.wp.com/mmx.prnasia.com/media/MS1337864/Binance-Logo-Yellow-4x-Logo.jpg?resize=260%2C140&ssl=1 "Binance Introduces Agent OS to Connect AI Applications to Financial Infrastructure") ## Binance Introduces Agent OS to Connect AI Applications to Financial Infrastructure New developer platform connects AI applications to Binance trading, market data,…